BNTX vs. RVTY: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at BNTX and RVTY, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
BNTX trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, RVTY is a standard domestic listing.
| Symbol | BNTX | RVTY |
|---|---|---|
| Company Name | BioNTech SE | Revvity, Inc. |
| Country | Germany | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 26.76 billion USD | 10.64 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | October 10, 2019 | February 21, 1973 |
| Security Type | ADR | Common Stock |
Historical Performance
This chart compares the performance of BNTX and RVTY by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | BNTX | RVTY |
|---|---|---|
| 5-Day Price Return | -1.24% | 2.52% |
| 13-Week Price Return | 13.80% | -2.76% |
| 26-Week Price Return | -9.35% | -18.76% |
| 52-Week Price Return | 23.76% | -23.74% |
| Month-to-Date Return | 3.53% | 4.32% |
| Year-to-Date Return | -2.33% | -17.84% |
| 10-Day Avg. Volume | 0.60M | 1.11M |
| 3-Month Avg. Volume | 0.99M | 1.31M |
| 3-Month Volatility | 45.29% | 36.53% |
| Beta | 1.53 | 0.99 |
Profitability
Return on Equity (TTM)
BNTX
-1.82%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
BNTX has a negative Return on Equity of -1.82%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
RVTY
3.71%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.55%
- Median
- 6.22%
- Q1
- 3.86%
- Min
- -6.95%
RVTY’s Return on Equity of 3.71% is in the lower quartile for the Life Sciences Tools & Services industry. This indicates a less efficient generation of profit from its equity base when compared to its competitors.
Net Profit Margin (TTM)
BNTX
-24.18%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
BNTX has a negative Net Profit Margin of -24.18%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
RVTY
10.19%
Life Sciences Tools & Services Industry
- Max
- 27.28%
- Q3
- 16.17%
- Median
- 7.24%
- Q1
- 3.00%
- Min
- -3.05%
RVTY’s Net Profit Margin of 10.19% is aligned with the median group of its peers in the Life Sciences Tools & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
BNTX
-47.73%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
BNTX has a negative Operating Profit Margin of -47.73%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
RVTY
13.57%
Life Sciences Tools & Services Industry
- Max
- 33.15%
- Q3
- 19.34%
- Median
- 13.02%
- Q1
- 8.05%
- Min
- -4.38%
RVTY’s Operating Profit Margin of 13.57% is around the midpoint for the Life Sciences Tools & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | BNTX | RVTY |
|---|---|---|
| Return on Equity (TTM) | -1.82% | 3.71% |
| Return on Assets (TTM) | -1.57% | 2.29% |
| Net Profit Margin (TTM) | -24.18% | 10.19% |
| Operating Profit Margin (TTM) | -47.73% | 13.57% |
| Gross Profit Margin (TTM) | 84.90% | 55.93% |
Financial Strength
Current Ratio (MRQ)
BNTX
8.61
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
BNTX’s Current Ratio of 8.61 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
RVTY
3.33
Life Sciences Tools & Services Industry
- Max
- 4.76
- Q3
- 2.77
- Median
- 1.85
- Q1
- 1.40
- Min
- 0.43
RVTY’s Current Ratio of 3.33 is in the upper quartile for the Life Sciences Tools & Services industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
Debt-to-Equity Ratio (MRQ)
BNTX
0.01
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
BNTX’s Debt-to-Equity Ratio of 0.01 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
RVTY
0.43
Life Sciences Tools & Services Industry
- Max
- 1.75
- Q3
- 0.83
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
RVTY’s Debt-to-Equity Ratio of 0.43 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
BNTX
-1.43
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
BNTX has a negative Interest Coverage Ratio of -1.43. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
RVTY
15.30
Life Sciences Tools & Services Industry
- Max
- 29.61
- Q3
- 23.24
- Median
- 6.07
- Q1
- 2.18
- Min
- -14.08
RVTY’s Interest Coverage Ratio of 15.30 is positioned comfortably within the norm for the Life Sciences Tools & Services industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | BNTX | RVTY |
|---|---|---|
| Current Ratio (MRQ) | 8.61 | 3.33 |
| Quick Ratio (MRQ) | 8.48 | 2.75 |
| Debt-to-Equity Ratio (MRQ) | 0.01 | 0.43 |
| Interest Coverage Ratio (TTM) | -1.43 | 15.30 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
BNTX
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BNTX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
RVTY
0.32%
Life Sciences Tools & Services Industry
- Max
- 1.80%
- Q3
- 0.78%
- Median
- 0.37%
- Q1
- 0.00%
- Min
- 0.00%
RVTY’s Dividend Yield of 0.32% is consistent with its peers in the Life Sciences Tools & Services industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
BNTX
17.60%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
At 17.60%, BNTX’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
RVTY
11.88%
Life Sciences Tools & Services Industry
- Max
- 156.00%
- Q3
- 65.73%
- Median
- 23.81%
- Q1
- 0.00%
- Min
- 0.00%
RVTY’s Dividend Payout Ratio of 11.88% is within the typical range for the Life Sciences Tools & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | BNTX | RVTY |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.32% |
| Dividend Payout Ratio (TTM) | 17.60% | 11.88% |
Valuation
Price-to-Earnings Ratio (TTM)
BNTX
--
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for BNTX is currently unavailable.
RVTY
37.17
Life Sciences Tools & Services Industry
- Max
- 117.96
- Q3
- 65.59
- Median
- 37.26
- Q1
- 27.51
- Min
- 1.73
RVTY’s P/E Ratio of 37.17 is within the middle range for the Life Sciences Tools & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
BNTX
8.35
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
BNTX’s P/S Ratio of 8.35 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
RVTY
3.79
Life Sciences Tools & Services Industry
- Max
- 12.46
- Q3
- 6.70
- Median
- 4.24
- Q1
- 2.68
- Min
- 0.73
RVTY’s P/S Ratio of 3.79 aligns with the market consensus for the Life Sciences Tools & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
BNTX
1.19
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
BNTX’s P/B Ratio of 1.19 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
RVTY
1.51
Life Sciences Tools & Services Industry
- Max
- 7.99
- Q3
- 4.69
- Median
- 3.30
- Q1
- 1.88
- Min
- 1.02
RVTY’s P/B Ratio of 1.51 is in the lower quartile for the Life Sciences Tools & Services industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | BNTX | RVTY |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | 37.17 |
| Price-to-Sales Ratio (TTM) | 8.35 | 3.79 |
| Price-to-Book Ratio (MRQ) | 1.19 | 1.51 |
| Price-to-Free Cash Flow Ratio (TTM) | 196.39 | 21.07 |